Search
+
    SEARCHED FOR:

    HETERO LABS LTD

    Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption

    Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda injection were halted in July for technical evaluation. The new brands are manufactured by Hetero Labs, while distributors say the company may discontinue Obeda injectable supplies. Dr Reddy’s denies a replacement strategy.

    Hetero partners with Richter to develop, market Semaglutide injection globally

    Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic of Ozempic. This collaboration aims to expand global access to diabetes therapies. Regulatory filings are underway, with EU and US submissions planned for 2027. The partnership leverages Hetero's market presence and Richter's European network.

    Hyderabad Police Bust $250 mln cyber-intimidation racket targeting drug maker Hetero Group

    Hyderabad police have uncovered a sophisticated cyber-intimidation scheme. Perpetrators demanded a massive ransom from a Hetero Group employee. They threatened to share false information with the USFDA. This led to serious reputational and regulatory risks for the company. Police have arrested two individuals in connection with the racket.

    Sun Pharma, Hetero recall drugs in US market

    As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The Indian pharmaceutical industry is the world's third-largest by volume and 14th-largest in terms of value. India exported pharmaceuticals worth Rs 1,75,040 crore in the financial year 2021-22, including bulk drugs/ drug intermediates.

    Drugmakers seem to be in no hurry to launch Covid antiviral pill Paxlovid

    Several industry executives and doctors ET spoke to said at the moment, while cases are rising, the need for Paxlovid hasn't been felt as cases are mild and they also pointed to the bitter experience they had with molnupiravir in third wave, where they were left with lots of unsold stock and had to take write-offs.

    ICMR task force meets to discuss inclusion of Pfizer’s Paxlovid for Covid treatment

    Pfizer’s Paxlovid contains Nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and Ritonavir, which slows down Nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations. It’s administered as three tablets—two of Nirmatrelvir and one of Ritonavir—taken together orally twice daily for five days (30 tablets in total).

    The Economic Times
    BACK TO TOP